Document:

Plain English Warrant Agreement - TriplePoint Capital LLC

 Exhibit 4.14 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED
(“the 1933 ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO YOU
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 PLAIN ENGLISH WARRANT
AGREEMENT 
 This is a PLAIN ENGLISH WARRANT AGREEMENT dated September 18, 2009 by and between AMYRIS BIOTECHNOLOGIES,
INC., a California corporation, and TRIPLEPOINT CAPITAL LLC, a Delaware limited liability company. 
 The words “We”,
“Us”, or “Our” refer to the warrant holder, which is TRIPLEPOINT CAPITAL LLC. The words “You” or “Your” refers to the issuer, which is AMYRIS BIOTECHNOLOGIES, INC., and not to any individual. The words
“The Parties” refers to both TRIPLEPOINT CAPITAL LLC and AMYRIS BIOTECHNOLOGIES. This Plain English Warrant Agreement may be referred to as the “Warrant Agreement”. 

The Parties have entered into a Plain English Master Lease Agreement dated as of March 14, 2008, as amended September 18, 2009
and related Hardware or Software Facility Schedules and Summary Schedules which are collectively referred to in this Warrant Agreement as the “Lease Agreement”. 

In consideration of such Lease Agreement, the Parties agree to the following mutual agreements and conditions set forth below:

  

											
	WARRANT INFORMATION
	
Effective Date

September 18, 2009
	  	 Warrant Number

 0534-W-02
	  	
Lease Facility Schedules

0534-LE-02H; 0539-LE-02S

	 Warrant
Coverage
 $100,000 (5% of $2,000,000);
	  	 Number of
Shares
 8,026, subject to
adjustment per the
terms of
this Warrant
Agreement
	  	 Price Per Share

 $12.46, subject to
adjustment
per the terms of this
Warrant
Agreement
	  	 Type of
Stock
 Series C Preferred Stock, subject to adjustment per the terms of this Warrant
Agreement

  

					
	OUR CONTACT INFORMATION
	
Name

TriplePoint Capital LLC
	  	 Address For
Notices
 2755 Sand Hill Road, Ste. 150
Menlo Park, CA 94025
Tel: (650) 854-2090
Fax: (650) 854-1850
	  	 Contact
Person
 Sajal Srivastava, COO
Tel: (650) 233-2102
Fax: (650)
854-1850
email:legal@triplepointcapital.com

  

 1 

					
	YOUR CONTACT INFORMATION
	 Customer
Name
 Amyris Biotechnologies, Inc.
	  	 Address For
Notices
 5980 Horton St., Suite 450
Emeryville, CA 94608
	  	 Contact
Person
 Name: Jeryl Hilleman, CFO
Tel: (510) 450-0761 x734
Fax: (510) 450-0794
Email:
hilleman@amyris.com

  

	 1.
	 WHAT YOU AGREE TO GRANT US 

You grant to Us and We are entitled, upon the terms and subject to the conditions set forth in this Warrant Agreement, to purchase from
You, at a price per share equal to the Exercise Price, that number of fully paid and non-assessable shares of Your Warrant Stock equal to One Hundred Thousand Dollars ($100,000), divided by the Exercise Price. 

The number of shares of Warrant Stock and the Exercise Price of such Warrant Stock are subject to adjustment as provided in
Section 4 hereof. 
 For purposes of this Warrant Agreement, the following capitalized terms have the meanings given below:

 “Exercise Price” means the lower of (a) the lowest per share price for which Your preferred
stock is sold in the Next Round or (b) $12.46. 
 “Next Round’ means the next bona fide round of
equity financing in which You issue and sell shares of your preferred stock for aggregate gross cash proceeds of at least $1,000,000 (excluding any amounts received upon conversion or cancellation of indebtedness) subsequent to the Effective Date
(anticipated to be Your Series D Preferred). 
 “Warrant Stock” means (a) the class and series of
Your preferred stock issued in the Next Round, if the lowest per share price for which such preferred stock is sold in the Next Round is less than $12.46 per share, or (b) in all other cases, Your Series C Preferred Stock. 

Notwithstanding the above, if this Warrant Agreement is exercised prior to the Next Round then this Warrant Agreement
shall be exercisable for Your Series C Preferred Stock and the Exercise Price shall be $12.46 per share. 
 The Parties agree
that this Warrant Agreement to purchase the Warrant Stock has a fair market value equal to $100 and that $100 of the issue price is included as part of the leased value and will be allocable to the Warrant Agreement and the original issue discount
on the Lease Agreement shall be considered to be zero. 
  

 2 

	 2.
	 WHEN ARE WE ENTITLED TO PURCHASE YOUR WARRANT STOCK. 

The term of this Warrant Agreement and our right to purchase Warrant Stock will begin the Effective Date, and shall be available until
the earlier of (i) 10 years from the Effective Date or (ii) the effective date of Your initial public offering. 

Notwithstanding the foregoing, Our right to purchase the Warrant Stock shall be automatically and fully exercised via the net issuance
method described below (without surrender of the Warrant Agreement) upon the occurrence of a Merger Event, as defined below, with a Person that is not one of Your affiliates, in which Your common stock is exchanged for cash and/or stock that is
traded on a recognized public exchange or on the NASDAQ National Market, provided that, upon consummation of the Merger Event, the consideration payable to Us pursuant to such exercise and on account of the Warrant Stock consists of (i) cash or
(ii) stock that is traded on a recognized public exchange or on the NASDAQ National Market and the total per share consideration is equal to or greater than five (5) times the aggregate Exercise Price (as adjusted). No less than ten
(10) business days prior to any Merger Event, You shall provide Us with written notice of the proposed Merger Event together with a copy of the executed merger agreement, or other definitive documentation (and all schedules and exhibits
thereto) and information concerning Your expected capitalization immediately prior to the Merger Event. Upon consummation of the Merger Event, You shall promptly provide Us with (a) a copy of any modifications or amendments to the executed
merger agreement, (b) any other documents in connection therewith, (c) updated information, if any, concerning Your capitalization immediately prior to the Merger Event, and, (d) upon request, by Us any other information reasonably
necessary to an informed evaluation of Our rights under this Agreement. 
  

	 3.
	 HOW WE MAY PURCHASE YOUR WARRANT STOCK. 

We may exercise Our purchase rights, in Whole or in part, at any time, or from time to time, prior to the expiration of the term of this
Warrant Agreement, by giving You a completed and executed Notice of Exercise in the form attached as Exhibit I. Promptly upon receipt of the Notice of Exercise and in any event no later than twenty-one (21) days after you have
received Our Notice of Exercise and payment of the aggregate Exercise Price for the shares purchased, You will issue to Us a certificate for the number of shares of Warrant Stock that We have purchased and You will execute the Acknowledgment of
Exercise in the form attached hereto as Exhibit II indicating the number of shares which will be available to Us for future purchases, if any. 

We may pay for the Warrant Stock by either (i) cash or check, or (ii) by the net issuance method as determined below. If
We elect the Net Issuance method, You will issue Warrant Stock using the following formula: 
 X
= Y(A-B) 
     A 

 

			
	 Where X =
	  	 the number of shares of Warrant Stock to be issued to Us.

	Y =	  	 the number of shares of Warrant Stock We request to be exercised under this Warrant Agreement.

 

 3 

 A =         the
fair market value of one share of Warrant Stock. 
 B =
        the Exercise Price. 
 For purposes of the above calculation, current fair
market value of Warrant Stock shall mean with respect to each share of Warrant Stock: 
 If the exercise is in connection
with the initial public offering of Your Common Stock, and if Your registration statement relating to such public offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial
“Price to Public” specified in the final prospectus of the offering and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of such exercise; 

If this Warrant Agreement is exercised after, and not in connection with the Your initial public offering, and: 

 

	 Þ
	 if traded on a securities exchange, the fair market value shall be the product of (x) the average of the closing prices over a five
(5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the time of
such exercise; or 

  

	 Þ
	 if actively traded over-the-counter, the fair market value shall be the product of (x) the average of the closing bid and asked prices quoted
on the NASDAQ system (or similar system) over the five (5) day period ending three (3) days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which
each share of Warrant Stock is convertible at the time of such exercise. 

 If this Warrant Agreement is
exercised prior to or after Your initial public offering, and: 
  

	 Þ
	 Your Common Stock is not listed on any securities exchange or quoted in the NASDAQ System or the over-the-counter market, the current fair market
value of Warrant Stock shall be the product of (x) the fair market value of a share of Your Common Stock (the highest price per share which You could obtain from a willing buyer (not a current employee or director) for shares of Common Stock
sold, from authorized but unissued shares), as determined in good faith by Your Board of Directors and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible at the lime of such exercise, unless You shall
become subject to a merger, acquisition or other consolidation pursuant to which You are not the surviving party, in which case the fair market value of Warrant Stock shall be deemed to be the value received by the holders of the Your Warrant Stock
on a common equivalent basis pursuant to such merger or acquisition or other consolidation. 

 During the term
of this Warrant Agreement, You will at all times from and after the Effective Date have authorized and reserved a sufficient number of shares of (a) Warrant Stock to provide for the exercise of our rights to purchase Warrant Stock, and
(b) Common Stock to provide for the conversion of the Warrant Stock. 
  

 4 

 If We elect to exercise part of the Warrant Agreement, You will promptly issue to Us an
amended Warrant Agreement stating the remaining number of shares that are available. All other terms and conditions of that amended Warrant Agreement shall be identical to those contained in this Warrant Agreement. 

If at the end of the term of this Warrant Agreement, the fair market value of one share of Warrant Stock (or other security issuable upon
the exercise hereof) as determined in accordance herewith is greater than the Exercise Price in effect on such date, then this Warrant Agreement shall automatically be deemed on and as of such date to be converted pursuant hereto as to all shares of
Warrant Stock (or such other securities) for which it shall not previously have been exercised or converted, and You shall promptly deliver a certificate representing the shares of Warrant Stock (or such other securities) issued upon such conversion
to Us. 
  

	 4.
	 WHEN WILL THE NUMBER OF SHARES AND EXERCISE PRICE CHANGE. 

 

	 Þ
	 If You are Acquired. If at any time: (i) there is a reorganization of Your stock (other than a reclassification, exchange or subdivision
of Your stock otherwise provided for in this Warrant Agreement); (ii) You merge or consolidate with or into another entity, whether or not You are the surviving entity: (iii) You sell or convey, or grant an exclusive license with respect
to, all or substantially all of Your assets to any other person; or (iv) there occurs any transaction or series of related transactions that result in the transfer of fifty percent (50%) or more of the outstanding voting power of the
capita] stock of You (each of the foregoing events are referred to as a “Merger Event”), then, as a part of such Merger Event, lawful provision shall he made so that We shall thereafter he entitled to receive, upon exercise of Our rights
under this Warrant Agreement, the number of shares of preferred stock or other securities of the successor or surviving person resulting from such Merger Event, equal in value to that which would have been issuable if We had exercised Our rights
under this Warrant Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Your Board of Directors) shall be made in the application of the provisions of this Warrant Agreement
with respect to Our rights and interest after the Merger Event so that the provisions of this Warrant Agreement (including adjustments of the Exercise Price and number of shares of Warrant Stock purchasable) shall be applicable to the greatest
extent possible. 

  

	 Þ
	 If You Reclassify Your Stock. If at any time You combine, reclassify, exchange or subdivide Your securities or otherwise, change any of the
securities as to which purchase rights under this Warrant Agreement exist into the same or a different number of securities of any other class or classes, this Warrant Agreement will thereafter represent the right to acquire such number and kind of
securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Warrant Agreement immediately prior to such combination, reclassification, exchange, subdivision
or other change. 

  

	 Þ
	 If You Subdivide or Combine Your Shares. If at any time You combine or subdivide Your Warrant Stock, the Exercise Price will be
proportionately decreased in the case of a subdivision, or proportionately increased in the case of a combination. 

  

 5 

	 Þ
	 If You Pay Stock Dividends. If at any time You pay a dividend payable in, or make any other distribution (except any distribution
specifically provided for in the above paragraphs) of Your Warrant Stock, then the Exercise Price shall be adjusted, from and after the record date of such dividend or distribution, to that price determined by multiplying the Exercise Price in
effect immediately prior to such record date by a fraction (i) the numerator of which shall be the total number of all shares of Your Warrant Stock outstanding immediately prior to such dividend or distribution, and (ii) the denominator of
which shall be the total number of all shares of Your Warrant Stock outstanding immediately after such dividend or distribution. We will thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of shares
of Warrant Stock (calculated to the nearest whole share) obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of shares of Warrant Stock issuable upon the exercise hereof immediately prior to such
adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. 

  

	 Þ
	 If You Change the Antidilution Rights of the Warrant Stock or Issue New Preferred or Convertible Stock. All antidilution rights applicable to
the Warrant Stock purchasable under this Warrant Agreement are as set forth in Your Certificate of Incorporation, as amended through the Effective Date. You will promptly provide Us with any restatement, amendment, modification of or waiver of any
right under Your Certificate of Incorporation. You will provide Us with any written notices relating to such antidilution rights provided to other holders of the Warrant Stock. 

 

	 5.
	 WE CAN TRANSFER THIS PLAIN ENGLISH WARRANT AGREEMENT. 

Subject to the terms and conditions contained in Section 7, We (or any successor transferee) may transfer in whole or in part this
Warrant Agreement and all its rights. You will record the transfer on Your books when You receive Our Notice of Transfer in the form attached hereto as Exhibit III, and Our payment of all transfer taxes and other governmental charges involved in
such transfer. 
  

	 6.
	 REPRESENTATIONS, WARRANTIES, AND COVENANTS FROM YOU. 

 

	 Þ
	 Reservation of Warrant Stock. The Warrant Stock issuable upon exercise of Our rights under this Warrant Agreement will be duly and validly
reserved and when issued in accordance with the provisions of this Warrant Agreement will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, however,
that the Warrant Stock issuable pursuant to this Warrant Agreement may be subject to restrictions on transfer under state and/or Federal securities laws, this Warrant Agreement and any other agreement between Us and You. Upon Our exercise, You will
issue to Us certificates for shares of Warrant Stock without charging Us any tax, or other cost incurred by You in connection with such exercise and the related issuance of shares of Warrant Stock. You will not be required to pay any tax, which may
be payable in respect of any transfer involved and the issuance and delivery of any certificate in a name other than TriplePoint Capital LLC. 

  

 6 

	 Þ
	 Due Authority. Your execution and delivery of this Warrant Agreement and the performance of Your obligations hereunder, including the
issuance to Us of the right to acquire the shares of Warrant Stock, have been duly authorized by all necessary corporate action on Your part, other than any amendment of the Company’s articles of incorporation necessary to authorize the Next
Round, and this Warrant Agreement is not inconsistent with the Your Certificate of Incorporation or Bylaws, subject to the accuracy of Our representations in Section 7 hereof, does not contravene any law or governmental rule, regulation or
order applicable to it, do not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which You are a party or by which You are bound, and this Warrant Agreement constitutes
a legal, valid and binding agreement, enforceable in accordance with its respective terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing
specific performance, injunctive relief and other equitable remedies. 

  

	 Þ
	 Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any
state, Federal or other governmental authority or agency is required with respect to execution, delivery and Your performance of Your obligations under this Warrant Agreement, except for the filing of any required notices pursuant to Federal and
state securities laws, which filings will be effective by the times required thereby and for the filing of any amendment to Your articles of incorporation authorizing Your Next Round. 

 

	 Þ
	 Issued Securities. All of Your issued and outstanding shares of Common Stock, Warrant Stock or any other securities have been duly authorized
and validly issued and are fully paid and nonassessable. To the extent applicable all outstanding shares of Common Stock and Warrant Stock were issued in full compliance with all Federal and state securities laws. In addition as of the Effective
Date: 

 Your authorized capital consists of (A) 33,000,000 shares of Common Stock, of which 5,029,830
shares of Common Stock are issued and outstanding, and (B) 21,080,641 shares of preferred stock, of which 16,547,462 shares are issued and outstanding. 

You have reserved 5,942,700 shares of Common Stock for issuance under Your Stock Incentive Plan, under which 3,405,762 options have been
granted. Except as otherwise provided in this Warrant Agreement and as noted above, there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares
of the Your capital stock or other of Your securities. 
 Except as set forth in Your Investor’s Rights Agreement, a true,
correct and complete copy of which has been delivered to Us prior to the issuance of this Warrant, and the Lease Agreement, Your stockholders do not have preemptive rights to purchase new issuances of Your capital stock. 

 

	 Þ
	 Other Commitments to Register Securities. As of the Effective Date, except as set forth in this Warrant Agreement and the Investors’
Rights’ Agreement, You are not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under 

 

 7 

	 	
the 1933 Act any of Your presently outstanding securities or any of Your securities which may hereafter be issued. 

 

	 Þ
	 Exempt Transaction. Subject to the accuracy of Our representations in Section 7 hereof, the issuance of the Warrant Stock upon exercise
of this Warrant Agreement will constitute a transaction exempt front (i) the registration requirements of Section 5 of the 1933 Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable
state securities laws. 

  

	 Þ
	 Compliance with Rule 144. We may sell the Warrant Stock issuable hereunder in compliance with Rule 144 promulgated by the Securities and
Exchange Commission. Upon exercise of this warrant, we will be obligated to become a party to the Investors’ Rights Agreement and, pursuant thereto, shall be entitled to the benefit of Your covenants with respect to Your compliance with the
filing requirements of the Securities and Exchange Commission as set forth in such Rule 144, as may be amended. 

  

	 Þ
	 No Impairment. You agree not to, by amendment of Your Articles of Incorporation or through a reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by You, but shall at all times in
good faith assist in carrying out all the provisions of this Warrant and in taking all such action as may be necessary or appropriate to protect Our rights under this Warrant against impairment, However, You shall not be deemed to have impaired Our
rights if You amend Your Articles of Incorporation or Your Investor’s Rights Agreement or similar agreements, or the holders of Your equity securities waive their rights thereunder, in a manner that does not (individually or when considered in
the context of any other actions being taken in connection with such amendments or waivers) affect Us in a manner different from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the
Warrant Stock. 

  

	 7.
	 OUR REPRESENTATIONS AND COVENANTS TO YOU. 

  

	 Þ
	 Investment Purpose. The right to acquire Warrant Stock or the Warrant Stock issuable upon exercise of Our rights contained herein and the
Common Stock issuable upon conversion will be acquired for investment purposes and not with a view to the sale or distribution of any part thereof, and We have no present intention of selling or engaging in any public distribution of the same in
violation of the 1933 Act. 

  

	 Þ
	 Private Issue. We understand (i) that this Warrant Agreement, the Warrant Stock issuable upon exercise of this Warrant Agreement and the
Common Stock issuable upon conversion of the Warrant Stock are not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Warrant Agreement will be exempt from the
registration and qualifications requirements thereof, and (ii) that Your reliance on such exemption is predicated on the representations set forth in this Section 7. 

 

	 Þ
	 Disposition of Our Rights. In no event will We make a disposition of any of Our rights to acquire Warrant Stock or Warrant Stock issuable
upon exercise of such rights or the 

  

 8 

	 	
Common Stock issuable upon conversion of the Warrant Stock unless and until (i) We shall have notified You in writing of the proposed disposition, and (ii) the transferee agrees to be
bound in writing to the applicable terms and conditions of this Warrant Agreement, and (iii) if You request, We shall have furnished You with an opinion of counsel satisfactory to You and Your counsel to the effect that (A) appropriate
action necessary for compliance with the 1933 Act has been taken, or (B) an exemption from the registration requirements of the 1933 Act is available. Notwithstanding the foregoing, the restrictions imposed upon the transferability of any of
Our rights to acquire Warrant Stock or Warrant Stock issuable on the exercise of such rights or the Common Stock issuable upon conversion of the Warrant Stock do not apply to transfers from the beneficial owner of any of the aforementioned
securities to its nominee or from such nominee to its beneficial owner, and shall terminate as to any particular share of Warrant Stock when (1) such security shall have been effectively registered under the 1933 Act and sold by the holder
thereof in accordance with such registration or (2) such security shall have been sold without registration in compliance with Rule 144 under the 1933 Act, or (3) a letter shall have been issued to You at Our request by the staff of the
Securities and Exchange Commission or a ruling shall have been issued to the You at Our request by such Commission stating that no action shall be recommended by such staff or taken by such Commission, as the case may be, if such security is
transferred without registration under the 1933 Act in accordance with the conditions set forth in such letter or ruling and such letter or ruling specifies that no subsequent restrictions on transfer are required. Whenever the restrictions imposed
hereunder shall terminate, as hereinabove provided, the holder of a share of Warrant Stock then outstanding as to which such restrictions have terminated shall be entitled to receive from You, without expense to such holder, one or more new
certificates for the Warrant or for such shares of Warrant Stock not bearing any restrictive legend referring to 1933 Act registration or exemption. 

  

	 Þ
	 Financial Risk. We have such knowledge and experience in financial and business matters and knowledge of Your business affairs and financial
condition as to be capable of evaluating the merits and risks of Our investment, and have the ability to bear the economic risks of Our investment. 

  

	 Þ
	 Risk of No Registration. We understand that if You do not register with the Securities and Exchange Commission pursuant to Section 12 of
the 1934 Act (the “1934 Act”), or file reports pursuant to Section 15(d), of the 1934 Act, or if a registration statement covering the securities under the 1933 Act is not in effect when We desire to sell (i) the rights to
purchase Warrant Stock pursuant to this Warrant Agreement, or (ii) the Warrant Stock issuable upon exercise of the right to purchase, or (iii) the Common Stock issuable upon conversion of the Warrant Stock, We may be required to hold such
securities for an indefinite period. We also understand that any sale of Our right to purchase Warrant Stock or Warrant Stock or Common Stock issuable upon conversion of the Warrant Stock, which might be made by it in reliance upon Rule 144 under
the 1933 Act may be made only in accordance with the terms and conditions of that Rule. 

  

	 Þ
	 Accredited Investor. We are an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D of
the 1933 Act, as presently in effect. 

  

 9 

	 8.
	 NOTICES YOU AGREE TO PROVIDE US. 

You agree to give Us at least twenty (20) days prior written notice of the following events: 

Þ if You Pay a Dividend or distribution declaration upon your stock. 

Þ If You offer for subscription pro-rata to the existing shareholders additional stock or
other rights. 
 Þ If You consummate a Merger Event. 

Þ If You have an IPO. 

Þ If You dissolve or liquidate. 

All notices in this Section must set forth details of the event, and if applicable, how the event adjusts either Our number of shares or
Our Exercise Price and the method used for such adjustment. 
  

	 9.
	 DOCUMENTS YOU WILL PROVIDE US. 

Upon the Effective Date, copies of 

Þ Certified Resolutions 

Þ Articles of Incorporation 

Þ Investor’s Rights Agreement 

Þ Bylaws 

Þ Any other documents and other information that We may reasonably request and are necessary
to implement the provisions and purposes of this Agreement. 
  

	 10.
	 REGISTRATION RIGHTS UNDER THE 1933 ACT. 

The shares of Your common stock into which the Warrant Stock is convertible shall have registration rights as set forth in the
Investors’ Rights Agreement, dated as of February 29, 2008, (as amended, restated or otherwise modified in accordance with its terms from time to time, the Investors’ Rights Agreement”) to the same extent and on the same terms
and conditions as possessed by the other Holders thereunder. The provisions set forth in Your Investors’ Right s Agreement relating to such registration rights shall not be amended or modified in a manner that treats Us in a manner different
from the effect that such amendments or waivers have on the rights of other holders of the same series and class as the Warrant Stock. By its receipt of this Warrant, the Holder agrees to be bound by the Investor Rights Agreement in so far as it
relates to such registration rights as a Holder pursuant thereto. 
  

 10 

	 11.
	 OTHER LEGAL PROVISIONS THE PARTIES WILL ABIDE BY. 

Effective Date. This Warrant Agreement shall he construed and shall be given effect in all respects as if it had been executed and
delivered by the Parties on the date hereof. This Warrant Agreement shall be binding upon any of the successors or assigns of the Parties. 

Attorney’s Fees. In any litigation, arbitration or court proceeding between the Parties relating to this Warrant Agreement,
the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant Agreement. 

Governing Law. This Warrant Agreement shall be governed by and construed for all purposes under and in accordance with the laws of
the State of California without giving effect to that body of law pertaining to conflicts of laws. 
 Consent to Jurisdiction
and Venue. All judicial proceedings arising in or under or related to this Warrant Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this agreement,
each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees
not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Plain English Warrant Agreement. Service of process on any
party hereto in any action arising out of or relating to this agreement shall be effective if given in accordance with the requirements for notice set forth in this Section, and shall be deemed effective and received as set forth therein. Nothing
herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 

Mutual Waiver of Jury Trial; Judicial Reference. Because disputes arising in connection with complex financial transactions are
most quickly and economically resolved by an experienced and expert person and The Parties wish applicable state and federal laws to apply (rather than arbitration rules), The Parties desire that their disputes be resolved by a judge applying such
applicable laws. EACH OF THE PARTIES SPECIFICALLY WAIVES ANY RIGHT THEY MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY
YOU AGAINST US OR OUR ASSIGNEE OR BY US OR OUR ASSIGNEE AGAINST YOU. IN THE EVENT THAT THE FOREGOING JURY TRIAL WAIVER IS NOT ENFORCEABLE, ALL CLAIMS, INCLUDING ANY AND ALL QUESTIONS OF LAW OR FACT RELATING THERETO, SHALL, AT THE WRITTEN REQUEST OF
ANY PARTY, BE DETERMINED BY JUDICIAL REFERENCE PURSUANT TO THE CALIFORNIA CODE OF CIVIL PROCEDURE (“REFERENCE”). THE PARTIES SHALL SELECT A SINGLE NEUTRAL REFEREE, WHO SHALL BE A RETIRED STATE OR FEDERAL JUDGE. IN THE EVENT THAT THE
PARTIES CANNOT AGREE UPON A REFEREE, THE REFEREE SHALL BE APPOINTED BY THE COURT. THE REFEREE SHALL REPORT A STATEMENT OF DECISION TO THE COURT. NOTHING IN THIS SECTION SHALL LIMIT THE RIGHT OF ANY PARTY AT ANY TIME TO EXERCISE LAWFUL SELF-HELP
REMEDIES, 
  

 11 

 
FORECLOSE AGAINST COLLATERAL OR OBTAIN PROVISIONAL REMEDIES. THE PARTIES SHALL BEAR THE FEES AND EXPENSES OF THE REFEREE EQUALLY UNLESS THE REFEREE ORDERS OTHERWISE. THE REFEREE SHALL ALSO
DETERMINE ALL ISSUES RELATING TO THE APPLICABILITY, INTERPRETATION, AND ENFORCEABILITY OF THIS SECTION. THE PARTIES ACKNOWLEDGE THAT THE CLAIMS WILL NOT BE ADJUDICATED BY A JURY. This waiver extends to all such Claims, including Claims that involve
Persons other than You and Us; Claims that arise out of or are in any way connected to the relationship between You and Us; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising
out of this Warrant Agreement. 
 Counterparts. This Warrant Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 Notices.
Any notice required or permitted under this Warrant Agreement shall be given in writing and shall be deemed effectively given upon the earlier of (1) actual receipt or 3 days after mailing if mailed postage prepaid by regular or airmail to Us
or You or (2) one day after it is sent by overnight mail via nationally recognized courier or (3) on the same day as sent via confirmed facsimile transmission, provided that the original is sent by personal delivery or mail by the sending
party. 
 Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce
its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where such party will not have an adequate
remedy at law and where damages will not be readily ascertainable. Each party expressly acknowledges and agrees that there is no adequate remedy at law for any breach of this Warrant Agreement and that in the event of any breach of this Agreement,
the injured party shall be entitled to specific performance of any or all provisions hereof or an injunction prohibiting the other party from continuing to commit any such breach of this Agreement. 

Survival. The representations, warranties, covenants, and conditions of the Parties contained herein or made pursuant to this
Warrant Agreement shall survive the execution and delivery of this Warrant Agreement. 
 Severability. In the event any
one or more of the provisions of this Warrant Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall
be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 

Entire Agreement. This Warrant Agreement constitutes the entire agreement between the Parties pertaining to the subject matter
contained in it and supersedes all prior and contemporaneous agreements, representations and undertakings of the Parties, whether oral or written, with respect to such subject matter. 

 

 12 

 Amendments. Any provision of this Warrant Agreement may only be amended by a written
instrument signed by the Parties. 
 Lost Warrants or Stock Certificates. You covenant to Us that, upon receipt of
evidence reasonably satisfactory to Us of the loss, theft, destruction or mutilation of this Warrant Agreement or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to
You, or in the case of any such mutilation upon surrender and cancellation of such Warrant Agreement or stock certificate, You will make and deliver a new Warrant Agreement or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed
or mutilated Warrant Agreement or stock certificate. 
 Rights as Stockholders. We shall not, as a party to this Warrant
Agreement, be entitled to vote or receive dividends or be deemed the holder of Warrant Stock or any of Your other securities which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein he construed
to confer upon Us any of the rights of one of Your stockholders or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to receive dividends or subscription rights or otherwise until
this Warrant Agreement is exercised and the shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 

Facsimile Signatures. This Warrant Agreement may be executed and delivered by facsimile and upon such delivery the facsimile
signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 

(Signature Page to Follow) 
  

 13 

 IN WITNESS WHEREOF, each of the Parties have caused this Warrant Agreement to be
executed by its officers who are duly authorized as of the Effective Date. 
  

			
	 You:
	 	 AMYRIS BIOTECHNOLOGIES, INC.

		
	 Signature:
	 	 /s/ John G. Melo

		
	 Print Name:
	 	 John G. Melo

		
	 Title:
	 	 CEO

		
	 Us:
	 	 TRIPLEPOINT CAPITAL LLC

		
	 Signature:
	 	 /s/ Sajal Srivastava

		
	 Print Name:    
	 	 Sajal Srivastava

		
	 Title:
	 	 Chief Operating Officer

[SIGNATURE PAGE TO PLAIN ENGLISH WARRANT AGREEMENT 0534-W-02] 

 

 14 

 EXHIBIT I 

NOTICE OF EXERCISE 

To:
[                                    ] 

 

	 1.
	 We hereby elect to purchase
[                    ] shares of the Series
[                    ] Preferred Stock of
[                    ], pursuant to the terms of the Plain English Warrant Agreement dated the
[                    ] day of
[                    ], [200    ] (the “Plain English Warrant Agreement”) between You and Us. We hereby
tender here payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any. 

  

	 2.
	 Method of Exercise (Please initial the applicable blank) 

 

	 	 a.
	                      The undersigned
elects to exercise the Plain English Warrant Agreement by means of a cash payment, and gives You full payment for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any. 

 

	 	 b.
	                      The undersigned
elects to exercise the Plain English Warrant Agreement by means of the Net Issuance Exercise method of Section 3 of the Plain English Warrant Agreement. 

 

	 3.
	 In exercising Our rights to purchase the Series
[                    ] Preferred Stock of
[                    ], We hereby confirm and acknowledge the investment representations, warranties and covenants made in Section 7 of
the Plain English Warrant Agreement. 

 Please issue a certificate or certificates representing these
purchased shares of Series [                    ] Preferred Stock in Our name or in such other name as is specified below. 

 

					
	 	 	  
		 	 (Name)

		
	 	 	  
		 	 (Address)

			
		 	 US:
	 	 TRIPLEPOINT CAPITAL LLC

			
		 	 By:
	 	 
			
		 	 Title:  
	 	 
			
		 	 Date:
	 	 

  

 15 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 

[                      
                      ], hereby acknowledges receipt of the “Notice of Exercise” from TRIPLEPOINT CAPITAL LLC, to purchase
[                    ] shares of the Series
[                    ] Preferred Stock of
[                    ], pursuant to the terms of the Plain English Warrant Agreement, and further acknowledges that
[                    ] shares remain subject to purchase under the terms of the Plain English Warrant Agreement. 

YOU: 

			
		
	 	 	 
		
	 By:
	 	 
		
	 Title:
	 	 
		
	 Date:  
	 	 

  

 16 

 EXHIBIT III 

TRANSFER NOTICE 

FOR VALUE RECEIVED, the foregoing Plain English Warrant Agreement and all rights evidenced thereby are hereby transferred and assigned to

  

			
		
		 	 
		 	 (Please Print)

Whose address is
                                         
                                         
           
  

 
  

			
	 Dated:
	 	 
		
	 Holder’s Signature:
	 	 
		
	 Holder’s Address:
	 	 
		
	 Transferee’s Signature:
	 	 
		
	 Transferee’s Address:
	 	 
		
	 Signature Guaranteed:
	 	 

 NOTE: The signature to
this Transfer Notice must correspond with the name as it appears on the face of the Plain English Warrant Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other
representative capacity should file proper evidence of authority to assign the foregoing Plain English Warrant Agreement. 
  

 17Amendment No. 1 to Plain English Warrant Agreement

 Exhibit 4.15 

AMENDMENT NO. 1 TO PLAIN ENGLISH WARRANT AGREEMENT 

This Amendment No. 1 to Plain English Warrant Agreement (this “Amendment”) is made and entered into as of
April 8, 2010 (the “Amendment Date”), by and among TriplePoint Capital LLC, a Delaware limited liability company (“TriplePoint”) and Amyris Biotechnologies, Inc., a California corporation (the
“Company”). 
 RECITALS 

WHEREAS, the Company and TriplePoint are parties to that certain Plain English Warrant Agreement dated September 18, 2009 (the
“Agreement”). 
 WHEREAS, the Company and TriplePoint desire to amend the Agreement. 

NOW, THEREFORE, in consideration of the matters described in the recitals above and the mutual promises, covenants and undertakings
contained herein, and intending to be legally bound hereby, the parties hereto agree as follows: 
 AMENDMENT 

1.      AMENDMENT TO AGREEMENT. The first paragraph of Section 2 shall be deleted in its
entirety and replaced with the following: 
 “(a) The term of this Warrant Agreement and our right to purchase Warrant Stock
will begin on the Effective Date, and shall be available until the earlier of (i) 10 years from the Effective Date or (ii) one (l) year from the effective date of an initial public offering of Your securities. 

(b) The settlement of the Warrant pursuant to this Warrant Agreement is to be made in Warrant Stock and, for the elimination of doubt, the
fact that the Warrant Stock delivered on exercise of the this Warrant Agreement is not registered under the Securities Act of 1933 will not in any way require you to settle the Warrant otherwise than in Warrant Stock, including, without limitation,
that there is no circumstance that would require You to net cash settle the Warrant. 
 (c) In case all the authorized Series C
Preferred Stock of the Company is converted, pursuant to the Company’s Articles of Incorporation, as may be amended from time to time, into Common Stock or other securities or property, or the Series C Preferred Stock otherwise ceases to exist,
then, We, upon exercise of the Warrant pursuant to this Warrant Agreement at any time after such time (the “Conversion Date”), shall receive, in lieu of the number of shares of Warrant Stock that would have been issuable upon
such exercise immediately prior to the Conversion Date (the “Former Number of Shares”), the stock and other securities and property which We would have been entitled to receive upon the Conversion Date if We had exercised the
Warrant pursuant to this Warrant Agreement with respect to the Former Number of Shares immediately prior to 

 
the Conversion Date (all subject to further adjustment as provided in this Warrant Agreement).” 

2.      NO OTHER AMENDMENTS. Except as expressly set forth above, all of the terms and conditions of
the Agreement remain in full force and effect. Notwithstanding anything else in this Amendment, if there is any conflict between subsections (b) and (c) in Section 1 above and the Agreement, the terms of the Agreement shall prevail.

 3.      GOVERNING LAW. This Amendment shall be governed by and construed under the
internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws. 

4.      COUNTERPARTS; FASCIMILE. This Amendment may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Amendment may be executed and delivered by facsimile, or by email in portable document format (.pdf) and delivery
of the signature page by such method will be deemed to have the same effect as if the original signature had been delivered to the other parties. 

[Remainder of page left blank] 
  

 2 

 IN WITNESS WHEREOF, each of the Company and TriplePoint has caused this Amendment
No. 1 to Plain English Warrant Agreement to be executed by its duly authorized representative, each as of the Amendment Date. 
  

													
	AMYRIS BIOTECHNOLOGIES, INC.	 		 		 	TRIPLEPOINT CAPITAL, LLC
				
	
 

	 		 		 	
 

							
	  By:	 	 Tamara L. Tompkins
	 		 		 		 	  By:	 	  

							
	  Its:	 	 General Counsel
	 		 		 		 	  Its:	 	  

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]